

## **Biologics4Life Patent-Pending Technology Provides New Clinical Option for Osteoporotic Patients**

Biologics4Life is pleased to announce that it has developed “Neo-S,” a patent-pending technology. Neo-S is a bone graft substitute combined with an active principle to form an advanced biomaterial which addresses the needs of patients with osteoporosis or bone metastasis. This patent will strengthen the company’s intellectual property portfolio and is a major step in the development of its range of combination orthobiologic materials.

“Neo-S is the result of 3 years of extensive research conducted by our creative multidisciplinary R&D team and our distinguished French academic partners; it will address unmet clinical needs in the treatment and prevention of fractures induced by metabolic bone disorders,” commented Sébastien Genesta, COO.

Biologics4Life, an early stage orthobiologics company, conceives, develops, and manufactures a range of patented biomaterials for bone regeneration. The company focuses on advanced biomaterials which provide modular, innovative options for treatment of bone voids and lesions.

For further information see: [www.biologics4life.fr](http://www.biologics4life.fr)

Or contact:

Ron Lowell

[ron.lowell@biologics4life.fr](mailto:ron.lowell@biologics4life.fr)